Original language | English (US) |
---|---|
Pages (from-to) | 1489-1492.e3 |
Journal | Journal of Allergy and Clinical Immunology |
Volume | 133 |
Issue number | 5 |
DOIs | |
State | Published - May 2014 |
ASJC Scopus subject areas
- Immunology and Allergy
- Immunology
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
The association between vitamin D status and the rate of exacerbations requiring oral corticosteroids in preschool children with recurrent wheezing. / Beigelman, Avraham; Zeiger, Robert S.; Mauger, David; Strunk, Robert C.; Jackson, Daniel J.; Martinez, Fernando D.; Morgan, Wayne J.; Covar, Ronina; Szefler, Stanley J.; Taussig, Lynn M.; Bacharier, Leonard B.
In: Journal of Allergy and Clinical Immunology, Vol. 133, No. 5, 05.2014, p. 1489-1492.e3.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - The association between vitamin D status and the rate of exacerbations requiring oral corticosteroids in preschool children with recurrent wheezing
AU - Beigelman, Avraham
AU - Zeiger, Robert S.
AU - Mauger, David
AU - Strunk, Robert C.
AU - Jackson, Daniel J.
AU - Martinez, Fernando D.
AU - Morgan, Wayne J.
AU - Covar, Ronina
AU - Szefler, Stanley J.
AU - Taussig, Lynn M.
AU - Bacharier, Leonard B.
N1 - Funding Information: This study was supported by the National Heart, Lung, and Blood Institute (grants 5U10HL064287 , 5U10HL064288 , 5U10HL064295 , 5U10HL064307 , 5U10HL064305 , and 5U10HL064313 ). This study is supported in part by the Washington University Institute of Clinical and Translational Sciences (grant no. UL1 TR000448 ), the National Center for Advancing Translational Sciences (subaward no. KL2 TR000450 ), the University of Wisconsin School of Medicine and Public Health Clinical and Translational Science Award (CTSA) (grant no. UL1 TR000427 ), and Colorado CTSA (grant no. 1 UL1RR025780 from the National Center for Research Resources/National Institutes of Health). This study was carried out in part in the General Clinical Research Centers at Washington University School of Medicine ( M01 RR00036 ), at National Jewish Health ( M01 RR00051 ), and at the University of New Mexico ( M01 RR00997 ). Funding Information: Disclosure of potential conflict of interest: A. Beigelman has received grants from the National Heart, Lung, and Blood Institute (NHLBI) , the KL2 Award , and Washington University's ICTS award and is employed by the Washington University School of Medicine. R. S. Zeiger has received grants from the NHLBI , Genentech , GlaxoSmithKline , Aerocrine , Merck , MedImmune , and Thermofisher and has consultant arrangements with Aerocrine, AstraZeneca, Genentech, GlaxoSmithKline, MedImmune, Schering Plough, Sunovion, and the NHLBI/Penn State. D. Mauger has received a grant from the NHLBI ; has received payment for providing writing assistance, medicines, equipment, or administrative support from AstraZeneca; and has consultant arrangements with GlaxoSmithKline, Boerhinger Ingelheim, and Merck. R. C. Strunk has received a grant from the NHLBI . D. J. Jackson has received grants from the National Institutes of Health (NIH) and Pharmaxis and has consultant arrangements with Gilead and GlaxoSmithKline. F. D. Martinez has received a grant from the NIH ; has consultant arrangements with MedImmune; has received payment for lectures from Abbott and Merck; and has received travel support from Abbott and Merck. W. J. Morgan has received grants from the NHLBI , the Cystic Fibrosis Foundation , and the National Institute of Allergy and Infectious Disease ; has consultant arrangements with the Cystic Fibrosis Foundation and Genentech; is employed by the University of Arizona; has received payment for lectures from Northwestern University, Indiana University, and St Jude's; and has received royalties from Elsevier. R. Covar has received grants from the NHLBI, GlaxoSmithKline, and Boehringer Ingelheim and has consultant arrangements with United Biosource. S. J. Szefler has received a grant, travel support, fees for participation in review activities, and payment for writing/reviewing the manuscript from the NHLBI; has consultant arrangements with Merck, Genentech, Boehringer Ingelheim, and GlaxoSmithKline; has received a grant from GlaxoSmithKline ; has received payment for lectures from Merck; has received payment for manuscript preparation from Genentech; and has patents planned through the NHLBI Childhood Asthma Research and Education Network. L. B. Bacharier has received grants from the NHLBI ; has consultant arrangements with Aerocrine, GlaxoSmithKline, Genentech/Novartis, Merck, Schering, Cephalon, and DBV; has received payment for lectures from Aerocrine, AstraZeneca, Genentech, GlaxoSmithKline, Merck, and Schering; and has received payment for manuscript preparation from First Consult. L. Taussig declares no relevant conflicts of interest.
PY - 2014/5
Y1 - 2014/5
UR - http://www.scopus.com/inward/record.url?scp=84899642811&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84899642811&partnerID=8YFLogxK
U2 - 10.1016/j.jaci.2014.02.024
DO - 10.1016/j.jaci.2014.02.024
M3 - Article
C2 - 24698320
AN - SCOPUS:84899642811
VL - 133
SP - 1489-1492.e3
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
SN - 0091-6749
IS - 5
ER -